Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies (SIGA) maintains this dedicated news hub for stakeholders tracking developments in biodefense therapeutics and public health preparedness. Access verified updates about the company's oral antiviral TPOXX, government contracts, and international health security initiatives.
This resource consolidates official announcements including regulatory milestones, strategic partnerships, and financial performance reports. Investors and public health professionals will find timely information on:
• TPOXX approvals and distribution updates
• Government procurement contracts
• Clinical research developments
• Financial disclosures and earnings
• Global health collaboration announcements
All content is sourced directly from company filings and press releases to ensure accuracy. Bookmark this page for efficient tracking of SIGA's progress in developing countermeasures against orthopoxviruses and other high-consequence pathogens.
Calidi Biotherapeutics has partnered with SIGA Technologies to advance its RTNova virotherapy for lung cancer and metastatic solid tumors. RTNova leverages a vaccinia virus enveloped by a human cell membrane to evade immunity and enhance therapeutic functions. SIGA will supply TPOXX, an antiviral agent against vaccinia virus, to support RTNova's development. This collaboration aims to create a universal treatment for all tumor types and will initially focus on lung cancer and metastatic solid tumors. RTNova's novel approach allows for easy administration and a broader patient reach. The partnership offers a safety mechanism for clinical trials, ensuring better regulatory compliance and patient safety.
SIGA Technologies, Inc. reported strong financial results for Q1 2024, with $24 million in product sales and $11 million in pre-tax operating income, showcasing growth over the previous year. The company highlighted focus on financial and operational excellence, TPOXX® franchise value, and team resilience. Recent developments include a new drug application in Japan and an amendment with Meridian Medical Technologies. SIGA also delivered $24 million of oral TPOXX in Q1, with a special cash dividend of $0.60 per share declared. The conference call and webcast to provide a business update are scheduled for May 7, 2024.
SIGA Technologies, a pharmaceutical company, will host a business update call on May 7, 2024, following the release of their first-quarter financial results. The call will feature the CEO and CFO and will be available via webcast and conference call. Participants can access the call through the company's website or by dialing in. A replay will be available for two weeks.
FAQ
What is the current stock price of Siga Technologie (SIGA)?
What is the market cap of Siga Technologie (SIGA)?
